Organoidsciences Ltd
476040
Company Profile
Business description
Organoidsciences Ltd is a three-dimensional cell structure created by self-organization. It has two products, ATORM, which is a medicine applied to various diseases and was developed using organoids derived from tissues such as intestines and salivary glands. ODISEI, an organoid-based new material evaluation solution, is an evaluation service for predicting the effects of various new materials, such as new drugs, foods, and cosmetics, when applied to the human body, and was developed using organoids for tumors, viruses, intestines, and skin.
Contact
338 Pangyo-ro
6th floor, Bundang-gu
Gyeonggi-do
Seongnam-si
KORT: +82 27072024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,028.30 | 98.90 | -1.08% |
| CAC 40 | 7,654.25 | 53.65 | -0.70% |
| DAX 40 | 23,487.33 | 550.00 | -2.29% |
| Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
| FTSE 100 | 9,116.69 | 79.65 | -0.87% |
| HKSE | 25,395.16 | 101.39 | -0.40% |
| NASDAQ | 21,279.63 | 175.92 | -0.82% |
| Nikkei 225 | 41,945.68 | 364.81 | -0.86% |
| NZX 50 Index | 13,054.58 | 78.58 | -0.60% |
| S&P 500 | 6,415.54 | 44.72 | -0.69% |
| S&P/ASX 200 | 8,757.70 | 101.30 | -1.14% |
| SSE Composite Index | 3,820.98 | 37.15 | -0.96% |